Brain somatic gene recombination (SGR) and the endogenous reverse transcriptases (RTs) that produce it have been implicated in the etiology of Alzheimer’s disease (AD), suggesting RT inhibitors as novel prophylactics or therapeutics. This retrospective, proof-of-concept study evaluated the incidence of AD in people with human immunodeficiency virus (HIV) with or without exposure to nucleoside RT inhibitors (NRTIs) using de-identified medical claims data. Eligible participants were aged ≥60 years, without pre-existing AD diagnoses, and pursued medical services in the United States from October 2015 to September 2016. Cohorts 1 (N = 46,218) and 2 (N = 32,923) had HIV. Cohort 1 had prescription claims for at least one NRTI within the exposure period; Cohort 2 did not. Cohort 3 (N = 150,819) had medical claims for the common cold without evidence of HIV or antiretroviral therapy. The cumulative incidence of new AD cases over the ensuing 2.75-year observation period was lowest in patients with NRTI exposure and highest in controls. Age- and sex-adjusted hazard ratios showed a significantly decreased risk for AD in Cohort 1 compared with Cohorts 2 (HR 0.88, p < 0.05) and 3 (HR 0.84, p < 0.05). Sub-grouping identified a decreased AD risk in patients with NRTI exposure but without protease inhibitor (PI) exposure. Prospective clinical trials and the development of next-generation agents targeting brain RTs are warranted.
1 October 2025 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
INTRODUCTION: To address knowledge gaps in Alzheimer's disease (AD) research, the Asian Cohort for Alzheimer's Disease (ACAD) Study will recruit over 5000 participants of Asian descent aged 60 or older in the United States and Canada. The current focus is on participants with Chinese, Korean, or Vietnamese ancestry, with the goal of characterizing both genetic and non‐genetic risk factors. ACAD has assembled a culturally and linguistically appropriate data collection protocol, as well as a biosample collection protocol. Recruitment strategies follow community‐based participatory research (CBPR) approaches to encourage research participation and engage Asian communities in brain health education. METHODS: The ACAD Clinical Core has developed a data collection packet (DCP) that gathers information on demographics, lifestyle factors, medical history, functional impairment, and cognitive status to support a dementia‐related consensus diagnosis. Questionnaires and cognitive tests in the DCP are carefully selected or adapted to strike balance between alignment with existing AD cohorts and capturing the uniqueness in Asian subpopulations that may be related to AD. ACAD conducts a 2‐year follow‐up visit with all participants and a second 2‐year follow‐up visit with those participants who received a diagnosis of mild cognitive impairment at the first follow‐up visit to confirm the robustness of the DCP and capture the trajectory of cognitive decline. DISCUSSION: ACAD is well positioned to address major challenges in recruitment, language barriers, and cultural appropriateness to ensure accurate assessment with the use of the DCP (developed in ACAD targeted languages) and multilingual research coordinators. Along with DNA and plasma biomarkers derived from biosamples, ACAD integrates comprehensive survey and cognitive data to facilitate multidimensional analyses. The data collection protocol is adaptable for other Asian subpopulations beyond ACAD's current focus, with an expectation of further bridging the gap in participant diversity within AD research. Highlights: Asian Americans and Asian Canadians constitute one of the fastest growing non‐White older populations. Asians have been under‐represented in American and Canadian AD research. The ACAD Study addresses that under‐representation in research. The study investigates Chinese, Vietnamese, and Korean genetic and non‐genetic risk factors for AD. The data collection protocol is adapted for Asians but maintains synergy with existing cohorts.